The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Identifying low- and high-risk AML
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the identification of high- and low-risk acute myeloid leukemia (AML). Patients are risk stratified at diagnosis based on morphologic, cytogenetic, and molecular genetic information. Various genetic alterations are typically associated with a different risk stratification: good, intermediate, or adverse. Dr Lachowiez discusses common mutations used to classify patients. Clinical characteristics are also considered, with secondary, therapy-related, and relapsed AML also regarded as high-risk. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
